Latest Eisai News & Updates
See the latest news and media coverage for Eisai. We track all announcements, press releases, and industry mentions in real time, all in one place.
Human health care company
eisai.com- Headquarters
- Bunkyo-Ku, Japan
- Company type
- Public company
- Number of employees
- 1,000–5,000
Last updated
Latest news about Eisai
In short: Eisai faced an FDA review extension for subcutaneous Leqembi, while achieving approval in Canada and reporting strong drug safety and sales growth.
Company announcements
-
Eisai opens new Global Capability Centre
The IT hub in Visakhapatnam, India, standardizes global IT operations and drives digital transformation. An opening ceremony celebrated its launch.
-
Eisai receives human capital awards for third year
Eisai earns 'Thought Leaders of Human Capital 2025' and 'Human Capital Management Excellence 2025 Gold Award' for excellent management and disclosure.
-
Eisai announces FDA acceptance of LEQEMBI IQLIK sBLA
The application for subcutaneous starting dose in early Alzheimer’s is under priority review with action date May 24, 2026.
-
Eisai ranks 36th in Global 100 sustainability list
It marks Eisai's tenth inclusion and highest rank among global pharmaceutical companies. Evaluation based on UN SDGs, sustainable revenue, and investment.
Media coverage
-
Eisai (TSE:4523) Valuation Check After Recent Share Price Pullback And LEQEMBI Growth Story
Eisai stock performance snapshot Eisai (TSE:4523) has recently drawn attention after a one-month return of about a 9% decline and a past three-month gain of...
-
Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous I...
Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period by three...
-
FDA Extends Review of Eisai, Biogen Alzheimer’s Drug
The agency pushed its decision on weekly subcutaneous LEQEMBI IQLIK for early Alzheimer's initial treatment to Aug. 24 after seeking additional information.
-
Health Canada approves second drug targeting underlying cause of Alzheimer's disease
Health Canada has approved a second drug that targets the underlying cause of Alzheimer's disease, a development that could give Canadian patients more options to...
Track Eisai and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Eisai competitors & trending companies
Browse news for competitors to Eisai and other trending companies.
Lilly
Novartis
AbbVie
J&J
Otsuka Holdings
Zydus Group
Merck
Kyowa Kirin
Bayer
Dynatrace
Wolfspeed
Recursive
Global Partners
SELLAS
System1
Eventbrite
BuzzFeed
Ecopetrol
QCi
MARA
Microvast
Navitas
Plug
Alpha Tau
WhiteFiber
Circle
TAT
Jet.AI
Road Rental
Lucky Strike
Cheniere
Photronics
Sphere 3D
AMC
Carriage Services
Canaan